

# Christine Alewine

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7976172/publications.pdf>

Version: 2024-02-01

25  
papers

975  
citations

623188

14  
h-index

610482

24  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1445  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mesothelin Immunotherapy for Cancer: Ready for Prime Time?. <i>Journal of Clinical Oncology</i> , 2016, 34, 4171-4179.	0.8	244
2	Advances in Anticancer Immunotoxin Therapy. <i>Oncologist</i> , 2015, 20, 176-185.	1.9	161
3	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9008-9013.	3.3	108
4	Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2653-2661.	1.9	68
5	High mesothelin expression in advanced lung adenocarcinoma is associated with <i>KRAS</i> mutations and a poor prognosis. <i>Oncotarget</i> , 2015, 6, 11694-11703.	0.8	66
6	New Life for Immunotoxin Cancer Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1055-1058.	3.2	38
7	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 828-836.	3.2	35
8	Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response. <i>Clinical Cancer Research</i> , 2017, 23, 1564-1574.	3.2	32
9	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , 2020, 126, 4936-4947.	2.0	31
10	Molecular mediators of peritoneal metastasis in pancreatic cancer. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 1223-1243.	2.7	29
11	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	28
12	Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases. <i>Molecular Cancer Research</i> , 2020, 18, 229-239.	1.5	27
13	Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes. <i>Oncotarget</i> , 2017, 8, 9189-9199.	0.8	24
14	Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells. <i>JCI Insight</i> , 2019, 4, .	2.3	17
15	Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors. <i>Biomolecules</i> , 2020, 10, 973.	1.8	16
16	A phase II trial of the super-enhancer inhibitor Minnelide, in advanced refractory adenosquamous carcinoma of the pancreas. <i>Future Oncology</i> , 2022, 18, 2475-2481.	1.1	13
17	Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors. <i>Toxins</i> , 2018, 10, 447.	1.5	8
18	Caregiver Exclusion in the Age of COVID: Fighting Cancer With Half the Team. <i>Journal of Clinical Oncology</i> , 2021, 39, 1687-1688.	0.8	8

#	ARTICLE	IF	CITATIONS
19	Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice. PLoS ONE, 2014, 9, e104388.	1.1	8
20	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreaticobiliary cancer or other mesothelin expressing solid tumors.. Journal of Clinical Oncology, 2021, 39, TPS452-TPS452.	0.8	3
21	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreaticobiliary cancer.. Journal of Clinical Oncology, 2021, 39, 3051-3051.	0.8	3
22	Loss of ID3 in pancreatic cancer cells increases DNA damage without impairing MDC1 recruitment to the nuclear foci. Cancer Communications, 2022, 42, 269-272.	3.7	3
23	Furin is not required for processing of mesothelin precursor protein. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118967.	1.9	2
24	Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment. Translational Oncology, 2022, 21, 101440.	1.7	2
25	Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers. Molecular Cancer Therapeutics, 2021, 20, 2082-2092.	1.9	1